CHARM Alternative trial
Last reviewed 01/2018
The CHARM-Alternative trial recruited 2028 ACE inhibitor-intolerant patients with heart failure due to left ventricular dysfunction. The patients were randomised to either candesartan or placebo.
Treatment with candesartan (an angiotensin receptor antagonist) gave clear reductions in mortality and hospital admissions.
CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer
MA, Swedberg K; CHARM Investigators and Committees. (2003). Effects of candesartan
in patients with chronic heart failure and reduced left-ventricular systolic
function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative
trial. Lancet 362(9386):772-6.